In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients
Aditya Puri to Chair the Board of Stelis Biopharma, the proposed demerged Biotech Business of Strides
Posted On: 2021-02-04 01:37:49 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that the Board of Directors of the Company have approved in principle the demerger of its biotech business under Stelis Biopharma (Stelis). The demerger is expected to unlock significant value for Strides shareholders.
The Board will form a Committee of Directors to explore various options of value discovery including listing of the business on a standalone basis. The Committee will recommend the proposals to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward.
you re looking at it, the new york stock exchange, set to be taken over by a german trading house, okay there are a lot of folks wondering with the big board on the auction block, it s hard to believe, so you ask yourself what other parts of blue chip america may be up for sale to foreign entities. this is disturbing. fox business network s stuart varney joins me now. it s i think it s distressing to most americans to hear this german trading house is going to take over the stock exchange. hold on a second. i ve got another one for you. as of this morning the french is going to buy or have put a bid in for genzyme. now, that is an icon of the biotech business, it is the third largest biotech company in the world, it is an american company, headquartered in cambridge, massachusetts, it grew out of the high-tech research area around cambridge, it s about a 29, 30-year-old company, it s for sale, and the french are bidding. by the way, this joins the germans who took control of the ne